Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.51 |
| ▸ | SRC | P12931 | 5/20 | 0.51 |
| ▸ | PTK6 | Q13882 | 6/20 | 0.49 |
| ▸ | FYN | P06241 | 2/20 | 0.48 |
| ▸ | HCK | P08631 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | FRK | P42685 | 1/20 | 0.48 |
| ▸ | BLK | P51451 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | MTOR | P42345 | 5/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553302 | 0.96 | ABL1 (0.50) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL23157775 | 0.93 | ABL1 (0.52) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL19294568 | 0.82 | MTOR (0.69) | ABL1HDAC1MTORHDAC3HDAC2 | |
| SCHEMBL29939161 | 0.82 | MTOR (0.69) | ABL1HDAC1MTORHDAC3HDAC2 | |
| SCHEMBL20552997 | 0.79 | TGFBR1 (0.62) | FYNHDAC1MTORHDAC3HDAC2 | |
| SCHEMBL23251830 | 0.77 | MTOR (0.67) | ABL1SRCFYNHCKLCK | |
| SCHEMBL29669814 | 0.74 | PTK6 (0.43) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL19294566 | 0.74 | PTK6 (0.43) | ABL1SRCPTK6FYNHCK | |
| SCHEMBL7901628 | 0.74 | SRC (0.56) | ABL1SRCHCKMTORKDR | |
| SCHEMBL23157413 | 0.73 | MTOR (0.57) | ABL1HDAC1MTORHDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-04-03 | — | — | US | disclosed |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-3788050-B1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
| EP-3788049-B1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-02-23 | — | — | US | disclosed |
| US-20220340596-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-10-27 | — | — | US | disclosed |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | ABL1 463/4885SRC 579/4885PTK6 808/4885 |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ABL1 648/4885SRC 715/4885PTK6 183/4885 |
| US-20250108117-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | ABL1 953/4885SRC 971/4885PTK6 886/4885 |
| US-12048749-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ABL1 953/4885SRC 971/4885PTK6 886/4885 |
| US-12187746-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ABL1 648/4885SRC 715/4885PTK6 183/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | ABL1 648/4885SRC 715/4885PTK6 183/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ABL1 717/4885SRC 148/4885PTK6 1911/4885 |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | ABL1 953/4885SRC 971/4885PTK6 886/4885 |
| US-20220340596-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | ABL1 648/4885SRC 715/4885PTK6 183/4885 |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | ABL1 953/4885SRC 971/4885PTK6 886/4885 |
| US-12544448-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | RICTOR, MTOR, MLST8 | ABL1 2160/4885SRC 1785/4885PTK6 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.